Designed immune-suppressing dendritic cells safeguard against heart changes

Conrad, N. et al. examined trends and patterns in heart failure incidence through a population-based study of 4 million people. The findings were published in Lancet (2018).

Yan, T. et al. analyzed the burden, trends, and inequalities of heart failure globally from 1990 to 2019 in a secondary analysis based on the Global Burden of Disease 2019 study, reported in J. Am. Heart Assoc. (2023).

Khan, M. S. et al. delved into the global epidemiology of heart failure, sharing insights in Nat. Rev. Cardiol. (2024).

Greene, S. J. et al. provided a review on worsening heart failure, discussing nomenclature, epidemiology, and future directions in J. Am. Coll. Cardiol. (2023).

Adamo, L. et al. reassessed the role of inflammation in heart failure in Nat. Rev. Cardiol. (2020).

Markousis-Mavrogenis, G. et al. explored immunomodulation and immunopharmacology in heart failure, published in Nat. Rev. Cardiol. (2024).

Sabado, R. L. et al. investigated dendritic cell-based immunotherapy, as described in Cell Res. (2017).

Morante-Palacios, O. et al. discussed tolerogenic dendritic cells and their role in autoimmunity and inflammatory diseases in Trends Immunol. (2021).

Virani, S. S. et al. provided an update on heart disease and stroke statistics in the Circulation (2021) publication.

Ambrosy, A. P. et al. focused on the global health and economic burden of hospitalizations due to heart failure, detailing lessons from various registries in J. Am. Coll. Cardiol. (2014).

Jones, N. R. et al. presented a systematic review and meta-analysis on the survival of patients with chronic heart failure, featured in Eur. J. Heart Fail. (2019).

Cohn, J. N. et al. discussed the concepts and clinical implications of cardiac remodeling in a consensus paper published in J. Am. Coll. Cardiol. (2000).

Frantz, S. et al. examined left ventricular remodeling post-myocardial infarction, detailing pathophysiology, imaging, and novel therapies in Eur. Heart J. (2022).

Mann, D. L. explored the emerging role of innate immunity in the heart and vascular system in Circ. Res. (2011).

Murphy, S. P. et al. provided a state-of-the-art review on inflammation in heart failure, found in J. Am. Coll. Cardiol. (2020).

Monaco, C. et al. discussed immunotherapy for atherosclerosis in Physiol. Rev. (2025).

Hackstein, H. & Thomson, A. W. looked into dendritic cells as targets for immunosuppressive drugs in Nat. Rev. Immunol. (2004).

Tureci, O. et al. presented findings on the transcriptional induction during dendritic cell maturation in FASEB J. (2003).

Rurik, J. G. et al. explored CAR T cells produced in vivo for cardiac injury treatment in Science (2022).

Aghajanian, H. et al. targeted cardiac fibrosis with engineered T cells, presented in Nature (2019).

Du, H. et al. focused on CAR macrophages engineered in vivo to reduce myocardial ischemia-reperfusion injury in Circ. Res. (2025).

Wang, J. et al. investigated CAR-macrophage therapy’s potential in alleviating myocardial ischemia-reperfusion injury, published in Circ. Res. (2024).

Rong, Z. et al. provided insights on preventing immune rejection of human ESC-derived allografts in Cell Stem Cell (2014).

Todorova, D. et al. examined hESC-derived dendritic cells and their role in inducing immune tolerance in EBioMedicine (2020).

Greenwald, R. J. et al. revisited the B7 family in Annu. Rev. Immunol. (2005).

Sharma, P. et al. discussed immune checkpoint therapy and its future directions in Cell (2023).

Buchbinder, E. I. & Desai, A. compared CTLA-4 and PD-1 pathways, detailing implications of their inhibition in Am. J. Clin. Oncol. (2016).

Balaji, S. et al. explored the role of interleukin-10 in tissue repair in FASEB J. (2017).

Saraiva, M. et al. analyzed the biology and therapeutic potential of interleukin-10 in J. Exp. Med. (2020).

Forte, E. et al. discussed the interplay of immune and stromal cells in cardiac repair in Nat. Rev. Cardiol. (2018).

Bhattacharya, M. & Ramachandran, P. provided insights on human fibrosis immunology in Nat. Immunol. (2023).

Kim, J. et al. examined how wild-type p53 influences cancer metabolism in Cancer Cell (2019).

Pinto, A. R. et al. revisited cardiac cellular composition in Circ. Res. (2016).

Yao, L. et al. conducted spatial multiplexed protein profiling of cardiac ischemia-reperfusion injury in Circ. Res. (2023).

Li, Q. et al. studied the effects of small extracellular vesicles on angiogenesis post-myocardial infarction in Sci. Transl. Med. (2021).

Lindsey, M. L. et al. set guidelines for myocardial ischemia and infarction experimental models in Am. J. Physiol. Heart. Circ. Physiol. (2018).

Lindsey, M. L. et al. published guidelines for in vivo mouse models of myocardial infarction in Am. J. Physiol. Heart. Circ. Physiol. (2021).

Xiao, C. et al. investigated FMO2’s role in cardiac hypertrophy in Circulation (2025).

Hu, X. et al. conducted a large-scale investigation on the use of hypoxia-preconditioned allogeneic mesenchymal stem cells for myocardial repair in nonhuman primates, reported in Circ. Res. (2016).

Li, G. et al. presented a dynamic molecular atlas of cardiac fibrosis at single-cell resolution in Nat Cardiovasc Res. (2025).

Ackers-Johnson, M. et al. provided a simplified method for isolating cardiac myocytes and nonmyocytes from adult mouse hearts in Circ. Res. (2016).